Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1969

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

The influence of combined oral contraceptives on scalp hair growth. [Die

Wirkung monophasischer Ovulationshemmer auf das Wachstum der Kopfhaare.]

AUTHORS

Zaun H; Gerber T

SOURCE

Archivfuer Klinische und Experimentelle Dermatologie 234: 353-361. 1969.

ABSTRACT

The percent of telogen (resting) hairs was determined in 50 women before and during Cycles 1, 2, and 6 taking

various combined oral contraceptives. The pills used were chiefly Eugynon and Duoluton; the subjects used them

for gynecologic indications such as regulating the cycle, as well as for birth control. The results facilitated dividing

the subjects into 3 groups. Group 1 (14 women) had no change, their mean percentage of resting hairs ranged from

7.59 to 10.92%. Group 2 (25) showed an increase, averaging 7.54 before to 17.72, 14.76, and 9.13% telogen hairs

after 1, 3, and 6 cycles of pill intake. Group 3 (11) had 24.45% resting hairs before, then 13.31, 10.72, and 7.88%

during pill cycles. The latter 2 groups started with low and high rates, respectively, and ended with near normal

rates. 4 subjects exhibited dystrophic hair changes. (PubHealth.info Document ID: CONT9T 11-06)

PubHealth.info NOTE: The author(s) of this article titled, "The influence of combined oral contraceptives on scalp

hair growth. [Die Wirkung monophasischer Ovulationshemmer auf das Wachstum der Kopfhaare.]", is(are) Zaun H;

Gerber T. The source of this article is "Archivfuer Klinische und Experimentelle Dermatologie 234: 353-361. 1969.".

This article was published in 1969 in German language(s). (PubHealth.info® Document ID: CONT9T 11-06. All rights

reserved with PubHealth.info) PIN: 40011

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.